# EDGAR Filing Document

**Accession Number:** 0000031462
**File Stem:** 0001558370-23-001231
**Filing Date:** 2023-2
**Character Count:** 92012
**Document Hash:** 565b7d1c5996b121d1285d849879e32a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001558370-23-001231.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001558370-23-001231

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 39

**CONFORMED PERIOD OF REPORT**: 20230214

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Cost Associated with Exit or Disposal Activities

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ECOLAB INC.
- **CENTRAL INDEX KEY:** 0000031462
- **STANDARD INDUSTRIAL CLASSIFICATION:** SOAP, DETERGENT, CLEANING PREPARATIONS, PERFUMES, COSMETICS [2840]
- **IRS NUMBER:** 410231510
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-09328
- **FILM NUMBER:** 23622688

**BUSINESS ADDRESS:**
- **STREET 1:** 1 ECOLAB PLACE
- **CITY:** SAINT PAUL
- **STATE:** MN
- **ZIP:** 55102
- **BUSINESS PHONE:** 18002326522

**MAIL ADDRESS:**
- **STREET 1:** 1 ECOLAB PLACE
- **CITY:** SAINT PAUL
- **STATE:** MN
- **ZIP:** 55102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ECOLAB INC
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ECONOMICS LABORATORY INC
- **DATE OF NAME CHANGE:** 19861203

?xml version='1.0' encoding='UTF-8'?

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **February 14, 2023**

**ECOLAB INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **1-9328** | **41-0231510** |
| (State or other jurisdiction<br>of incorporation) | (Commission<br>File No.) | (IRS Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **1 Ecolab Place, Saint Paul, Minnesota** | **55102** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code **1-800-232-6522**<br>

**(Not applicable)**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
| **Common Stock, $1.00 par value** | **ECL** | **New York Stock Exchange** |
| **2.625% Euro Notes due 2025** | **ECL 25** | **New York Stock Exchange** |
| **1.000% Euro Notes due 2024** | **ECL 24** | **New York Stock Exchange** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

Item 2.02 Results of Operations and Financial Condition.

On February 14, 2023, Ecolab Inc. ("Ecolab") announced earnings for the fourth quarter ended December 31, 2022. A copy of the (i) News Release issued by Ecolab in connection with this report under Item 2.02 is furnished and attached as Exhibit (99.1) and (ii) Supplemental Data to be used in connection with the conference call to be held discussing the fourth quarter results is furnished and attached as Exhibit (99.2), each of which is incorporated by reference herein. Ecolab also will publish the attached exhibits on its website located at www.ecolab.com.

Item 2.05 Costs Associated with Exit or Disposal Activities.

On February 14, 2023, Ecolab announced that it has expanded its previously announced Europe cost savings program to also focus on the Company's Institutional and Healthcare businesses in other regions. In connection with the expanded program, Ecolab now expects to incur pre-tax charges of $195 million ($150 million after tax). Ecolab expects that these restructuring actions will be completed by the end of 2024. Program actions include headcount reductions from terminations, not filling certain open positions and facility closures. The expanded program charges are expected to be primarily cash expenditures related to severance and asset disposals.

Cautionary Statements Regarding Forward Looking Information.

Statements contained in this Current Report on Form 8-K, including statements concerning Ecolab's restructuring plan, may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations of management of the company. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this report. In particular, the ultimate results of any restructuring and business improvement actions depend on a number of factors, including the development of final plans, the impact of local regulatory requirements regarding employee terminations, the time necessary to develop and implement the restructuring and other business improvement initiatives and the level of success achieved through such actions in improving competitiveness, efficiency and effectiveness. Additional risks and uncertainties that may affect operating results and business performance are set forth under Item 1A of our most recent Form 10-K, and the company's other public filings with the Securities and Exchange Commission. Ecolab does not undertake, and expressly disclaims, any duty to update any forward-looking statement whether as a result of new information, future events or changes in expectations, except as required by law.

Item 9.01 Financial Statements and Exhibits.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

The following exhibits are furnished pursuant to Item 2.02 of Form 8-K and should not be deemed to be "filed" under the Securities Exchange Act of 1934.

---

| | | |
|:---|:---|:---|
| **Exhibit No.** | **Description** | **Method Of Filing** |
| (99.1) | [Ecolab Inc. News Release dated February 14, 2023.](ecl-20230214xex99d1.htm) | Filed herewith electronically. |
| (99.2) | [Supplemental Data for Fourth Quarter dated February 14, 2023.](ecl-20230214xex99d2.htm) | Filed herewith electronically. |
| (104) | Cover Page Interactive Data File. | Embedded within the Inline XBRL document. |

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | ECOLAB INC. | ECOLAB INC. |
| Date: February 14, 2023 | By: | /s/ David F. Duvick |
|  |  | David F. Duvick |
|  |  | Assistant Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**

![A blue and white logo Description automatically generated with low confidence](ecl-20230214xex99d1001.jpg)

**News Release**

---

| | |
|:---|:---|
| <u>Investor Contact:</u> | <u>Media Contact:</u> |
| Andrew Hedberg (651) 250-2185 | Nigel Glennie (651) 250-2576 |
| Cairn Clark (651) 250-2291 |  |

---

**ECOLAB DELIVERS STRONG FOURTH QUARTER OPERATING PERFORMANCE**

**REPORTED DILUTED EPS $0.93; ADJUSTED DILUTED EPS $1.27**

**EXPECT FURTHER PERFORMANCE IMPROVEMENT THROUGH 2023**

**FOURTH QUARTER HIGHLIGHTS:**

&nbsp;&nbsp;&nbsp;&nbsp;● **Reported sales $3.7 billion, +9% versus last year. Acquisition adjusted fixed currency sales +12%, led by double-digit growth in the Industrial, Institutional & Specialty and Other segment, and improved growth in the Healthcare & Life Sciences segment.** 

&nbsp;&nbsp;&nbsp;&nbsp;● **Reported operating income +3%. Adjusted fixed currency operating income growth accelerated to +14%.** 

&nbsp;&nbsp;&nbsp;&nbsp;● **Reported diluted EPS $0.93. As expected, adjusted diluted EPS, excluding special gains and charges and discrete tax items were $1.27, -1%. Currency translation had a $0.10 per share unfavorable impact on EPS.** 

&nbsp;&nbsp;&nbsp;&nbsp;● **Fourth quarter cash flow from operating activities +$859 million, resulting in 97% free cash flow conversion for the full-year 2022.** 

&nbsp;&nbsp;&nbsp;&nbsp;● **Announced an expansion of Ecolab's previously disclosed $80 million Europe cost savings program focused on Institutional and Healthcare in other regions, resulting in a $175 million combined cost savings program.** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 |
|  | Reported | Reported |  | Adjusted | Adjusted |  |
| (unaudited) | Public Currency Rates | Public Currency Rates | %  | Public Currency Rates | Public Currency Rates | %  |
| (millions, except per share) | **2022** | 2021 | Change | **2022** | 2021 | Change |
| Net sales | **$3671.2** | $3364.6 | 9% | **$3671.2** | $3352.6 | 10% |
| Operating income | **399.2** | 387.7 | 3% | **502.4** | 475.1 | 6% |
| Net income attributable to Ecolab | **264.4** | 301.0 | (12)% | **363.6** | 369.3 | (2)% |
| Diluted earnings per share attributable to Ecolab | **$0.93** | $1.04 | (11)% | **$1.27** | $1.28 | (1)% |
|  |  |  |  | Adjusted | Adjusted |  |
|  | Fixed Currency Rates | Fixed Currency Rates | %  | Fixed Currency Rates | Fixed Currency Rates | %  |
|  | **2022** | 2021 | Change | **2022** | 2021 | Change |
| Net sales | **$3836.2** | $3326.0 | 15% | **$3836.2** | $3314.0 | 16% |
| Operating income | **430.7** | 378.9 | 14% | **533.9** | 466.3 | 14% |

---

------

ST. PAUL, Minn., February 14, 2023

**CEO Comment**

Christophe Beck, Ecolab's chairman and chief executive officer, said, "We delivered the fourth quarter with strong operating performance in line with our expectations, finishing 2022 with good momentum as fixed currency adjusted operating income growth accelerated to 14%. Our sales growth remained strong with double-digit pricing that continued to exceed substantial delivered product cost inflation. As anticipated, volumes were impacted by softening demand, particularly in Europe, though volumes outside of Europe remained stable versus last year. I am proud of our team's execution in the fourth quarter and throughout 2022 to navigate the challenging global environment, maintaining double-digit fixed currency sales growth by delivering for our customers.

"We enter 2023 from a position of strength and expect our performance to improve over the course of the year. This is despite a challenging macro environment characterized by high delivered product costs and easing demand, as well as unfavorable impacts from higher interest expense and currency translation. Our focus is on driving strong sales growth and capturing the significant operating margin expansion opportunity we see ahead of us as we leverage our leading customer value proposition and expanded cost savings program.

"With additional pricing actions, easing inflationary pressures, new business wins, new innovation, and further productivity benefits, we anticipate double-digit growth in adjusted operating income in 2023. This strong performance is expected to more than overcome the challenging environment to deliver quarterly adjusted earnings per share growth that accelerates towards our low double-digit historical performance."

**Fourth Quarter 2022 Consolidated Results** 

Ecolab's fourth quarter reported sales increased 9%, fixed currency sales increased 15%, and acquisition adjusted fixed currency sales increased 12% when compared to the prior year.

Fourth quarter 2022 reported operating income increased 3% and includes the impact of special gains and charges, which were a net charge primarily related to restructuring costs. Adjusted fixed currency operating income increased 14%. Acquisition adjusted fixed currency operating income

------

increased 10%, as accelerating pricing overcame substantially higher delivered product costs, investments in the business, and unfavorable mix.

Reported other expense increased $15 million in the fourth quarter of 2022, driven by a $26 million settlement expense related to U.S. pension plan lump-sum payments to retirees.

Reported interest expense increased 56% reflecting debt issued to fund the Purolite acquisition and the impact from higher average interest rates on floating rate debt.

The reported income tax rate for the fourth quarter of 2022 was 16.2% compared with the reported rate of 12.6% in the fourth quarter of 2021. Excluding special gains and charges, discrete tax items and the 2021 impact of the Purolite transaction, the adjusted tax rate for the fourth quarter of 2022 was 18.2% compared with the adjusted tax rate of 17.3% in the fourth quarter of 2021. The higher adjusted tax rate in the fourth quarter of 2022 reflected the timing of tax planning benefits in the prior year.

Reported net income decreased 12% versus the prior year. Excluding the impact of special gains and charges, discrete tax items and the 2021 impact of the Purolite transaction, adjusted net income decreased 2% versus the prior year.

Reported diluted earnings per share decreased 11% versus the prior year. Adjusted diluted earnings per share decreased 1% when compared against the fourth quarter of 2021. Currency translation had a $0.10 unfavorable impact on fourth quarter 2022 earnings per share.

Ecolab repurchased approximately 0.5 million shares of its common stock during the fourth quarter of 2022 to complete the previously announced $500 million share repurchase program.

------

**Fourth Quarter 2022 Segment Review**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Global Industrial** |  |  |  |  |
| (unaudited) | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 |  | Acq. Adj. |
| (millions) | **2022** | 2021 | % Change | % Change |
| Fixed currency |  |  |  |  |
| &nbsp;&nbsp;Sales | **$1866.2** | $1634.6 | 14% | 14% |
| &nbsp;&nbsp;Operating income | **283.8** | 266.0 | 7% | 7% |
| &nbsp;&nbsp;Operating income margin | **15.2%** | 16.3% |  |  |
| &nbsp;&nbsp;Acq. adj. operating income margin | **15.2%** | 16.3% |  |  |
| Public currency |  |  |  |  |
| &nbsp;&nbsp;Sales | **$1779.8** | $1659.2 | 7% |  |
| &nbsp;&nbsp;Operating income | **267.6** | 272.1 | (2)% |  |

---

The Industrial segment includes Water, Food & Beverage, Downstream and Paper

Acquisition adjusted fixed currency sales increased 14%. Growth was led by double-digit gains in Food & Beverage, Water and Paper. Acquisition adjusted fixed currency operating income increased 7% as accelerating pricing overcame significantly higher delivered product costs, investments in the business, and unfavorable mix.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Global Institutional & Specialty** |  |  |  |  |
| (unaudited) | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 |  | Acq. Adj. |
| (millions) | **2022** | 2021 | % Change | % Change |
| Fixed currency |  |  |  |  |
| &nbsp;&nbsp;Sales | **$1156.6** | $1044.1 | 11% | 11% |
| &nbsp;&nbsp;Operating income | **172.0** | 155.2 | 11% | 11% |
| &nbsp;&nbsp;Operating income margin | **14.9%** | 14.9% |  |  |
| &nbsp;&nbsp;Acq. adj. operating income margin | **14.9%** | 14.9% |  |  |
| Public currency |  |  |  |  |
| &nbsp;&nbsp;Sales | **$1124.6** | $1051.9 | 7% |  |
| &nbsp;&nbsp;Operating income | **165.5** | 157.0 | 5% |  |

---

The Institutional & Specialty segment includes Institutional and Specialty

Acquisition adjusted fixed currency sales increased 11%. Continued double-digit growth in the Institutional division reflected strong pricing and new business wins. Specialty sales showed strong growth, driven by robust quickservice sales growth and modest gains in food retail.

------

Acquisition adjusted fixed currency operating income increased 11% as accelerating pricing overcame higher delivered product costs and investments in the business.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Global Healthcare & Life Sciences** |  |  |  |  |
| (unaudited) | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 |  | Acq. Adj. |
| (millions) | **2022** | 2021 | % Change | % Change |
| Fixed currency |  |  |  |  |
| &nbsp;&nbsp;Sales | **$431.1** | $296.8 | 45% | 7% |
| &nbsp;&nbsp;Operating income | **67.7** | 28.4 | 138% | (18)% |
| &nbsp;&nbsp;Operating income margin | **15.7%** | 9.6% |  |  |
| &nbsp;&nbsp;Acq. adj. operating income margin | **8.7%** | 11.3% |  |  |
| Public currency |  |  |  |  |
| &nbsp;&nbsp;Sales | **$400.2** | $300.2 | 33% |  |
| &nbsp;&nbsp;Operating income | **61.0** | 29.0 | 110% |  |

---

The Healthcare & Life Sciences segment includes Healthcare and Life Sciences

Acquisition adjusted fixed currency sales increased 7% driven by double-digit growth in Life Sciences and improved Healthcare sales growth. As expected, Purolite delivered very strong performance, benefiting from its recent capacity additions. Acquisition adjusted fixed currency operating income decreased 18%, as accelerating pricing was more than offset by higher delivered product costs, unfavorable Healthcare volumes and mix, and targeted investments in the business.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Other** |  |  |  |  |
| (unaudited) | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 |  | Acq. Adj. |
| (millions) | **2022** | 2021 | % Change | % Change |
| Fixed currency |  |  |  |  |
| &nbsp;&nbsp;Sales | **$354.6** | $315.8 | 12% | 12% |
| &nbsp;&nbsp;Operating income | **59.2** | 43.1 | 37% | 37% |
| &nbsp;&nbsp;Operating income margin | **16.7%** | 13.6% |  |  |
| &nbsp;&nbsp;Acq. adj. operating income margin | **16.7%** | 13.6% |  |  |
| Public currency |  |  |  |  |
| &nbsp;&nbsp;Sales | **$339.2** | $318.2 | 7% |  |
| &nbsp;&nbsp;Operating income | **56.0** | 43.5 | 29% |  |

---

The Other segment includes Pest Elimination, Textile Care and Colloidal Technologies

------

Acquisition adjusted fixed currency sales increased 12%, reflecting double-digit growth across all divisions. Acquisition adjusted fixed currency operating income increased 37% as accelerating pricing overcame higher delivered product costs and investments in the business.

---

| | | |
|:---|:---|:---|
| **Corporate** |  |  |
| (unaudited) | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 |
| (millions) | **2022** | 2021 |
| Public currency |  |  |
| &nbsp;&nbsp;Sales | **$27.4** | $35.1 |
| &nbsp;&nbsp;Corporate operating expense |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Nalco and Purolite amortization | **47.7** | 30.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Special (gains) and charges | **103.2** | 83.6 |
| &nbsp;&nbsp;Total Corporate operating expense | **$150.9** | $113.9 |

---

Fourth quarter of 2022 corporate segment includes:

● sales of $27 million to ChampionX under the Master Cross Supply and Product Transfer agreements Ecolab entered into as part of the ChampionX separation

● amortization expense of $29 million related to the Nalco merger intangible assets and $19 million related to Purolite acquisition intangible assets

● special gains and charges were a net charge of $103 million, primarily related to restructuring costs

Special gains and charges for the fourth quarter of 2021 were a net charge of $84 million and primarily reflected COVID-related charges and Purolite acquisition costs.

**Expanded cost savings program**

Ecolab has expanded its previously announced $80 million Europe cost savings program to also focus on improving the performance of Institutional and Healthcare in other regions, resulting in an estimated $175 million of total annualized pre-tax savings ($135 million after-tax). The expanded program is designed to optimize the cost structure of the Company's Institutional and Healthcare businesses, repositioning Institutional for the new environment and returning Healthcare to profitable growth, as we continue to invest in other growth businesses. The savings are expected to be realized by the end of 2024.

------

In connection with the expanded program, Ecolab now expects to incur pre-tax charges of $195 million ($150 million after tax). The program charges are expected to be primarily cash expenditures related to severance and asset disposals, with additional savings expected from not filing open positions.

**Business Outlook**

**2023**

Ecolab expects to deliver performance that improves throughout 2023 despite a challenging macro environment characterized by high delivered product costs and easing demand. In addition, higher interest expense and currency translation are estimated to have a combined $0.30 per share unfavorable impact in 2023, or a 7% headwind to year-over-year earnings growth.

The Company expects double-digit growth in adjusted operating income, driven by continued robust sales growth, easing delivered product cost inflation, and improved productivity. This strong performance is expected to more than overcome the challenging environment to deliver quarterly adjusted earnings per share growth that accelerates towards our low double-digit historical performance.

**2023 – First Quarter**

Ecolab expects first quarter 2023 adjusted diluted earnings per share in the $0.82 to $0.90 range, compared with adjusted diluted earnings per share of $0.82 a year ago. This forecast includes an estimated unfavorable $0.13 per share impact from higher interest expense and currency translation, or a 15% headwind to year-over-year earnings growth.

The Company currently expects quantifiable special charges in the first quarter of 2023 to be approximately $0.15 per share, principally related to restructuring charges. Other than the special gains and charges noted above, other such amounts are not currently quantifiable.

**About Ecolab**

A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. Building on a century of innovation, Ecolab has annual sales of $14 billion, employs more than 47,000 associates and operates in more than 170 countries around the world.

------

The company delivers comprehensive science-based solutions, data-driven insights and world-class service to advance food safety, maintain clean and safe environments, and optimize water and energy use. Ecolab's innovative solutions improve operational efficiencies and sustainability for customers in the food, healthcare, life sciences, hospitality and industrial markets. www.ecolab.com

Ecolab will host a live webcast to review the fourth quarter earnings announcement today at 1:00 p.m. Eastern Time. The webcast, along with related materials, will be available to the public on Ecolab's website at www.ecolab.com/investor. A replay of the webcast and related materials will be available at that site.

**Cautionary Statements Regarding Forward-Looking Information** 

This news release contains certain statements relating to future events and our intentions, beliefs, expectations and predictions for the future which are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Words or phrases such as "will likely result," "are expected to," "will continue," "is anticipated," "we believe," "we expect," "estimate," "project," "may," "will," "intend," "plan," "believe," "target," "forecast" (including the negative or variations thereof) or similar terminology used in connection with any discussion of future plans, actions or events generally identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding global economic conditions, delivered product costs, demand, inflation, currency translation, our financial and business performance and prospects, including sales, earnings, pricing, margins, interest and pension expense, new business, productivity, and expectations concerning timing, amount and type of restructuring costs and savings from restructuring activities. These statements are based on the current expectations of management of the company. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this news release. In particular, the ultimate results of any restructuring initiative depend on a number of factors, including the development of final plans, the impact of local regulatory requirements regarding employee terminations, the time necessary to develop and implement the restructuring initiatives and the level of success achieved through such actions in improving competitiveness, efficiency and effectiveness.

Additional risks and uncertainties that may affect operating results and business performance are set forth under Item 1A of our most recent Form 10-K, and our other public filings with the

------

Securities and Exchange Commission (the "SEC"), and include the impact of economic factors such as the worldwide economy, capital flows, interest rates, foreign currency risk, reduced sales and earnings in our international operations resulting from the weakening of local currencies versus the U.S. dollar, demand uncertainty, supply chain challenges and inflation; the vitality of the markets we serve; exposure to global economic, political and legal risks related to our international operations, including geopolitical instability, the impact of sanctions or other actions taken by the U.S. or other countries, and retaliatory measures taken by Russia in response, in connection with the conflict in Ukraine; difficulty in procuring raw materials or fluctuations in raw material costs; our ability to attract, retain and develop high caliber management talent to lead our business and successfully execute organizational change and changing labor market dynamics; information technology infrastructure failures or breaches in data security; the effects and duration of the COVID-19 pandemic or other public health outbreaks, epidemics or pandemics; our ability to acquire complementary businesses and to effectively integrate such businesses, including Purolite; our ability to execute key business initiatives, including restructurings and our Enterprise Resource Planning system upgrades; our ability to successfully compete with respect to value, innovation and customer support; pressure on operations from consolidation of customers or vendors; restraints on pricing flexibility due to contractual obligations and our ability to meet our contractual commitments; the costs and effects of complying with laws and regulations, including those relating to the environment, climate change standards, and to the manufacture, storage, distribution, sale and use of our products, as well as to the conduct of our business generally, including labor and employment and anti-corruption; potential chemical spill or release; our commitments, goals, targets, objectives and initiatives related to sustainability; potential to incur significant tax liabilities or indemnification liabilities relating to the separation and split-off of our ChampionX business; the occurrence of litigation or claims, including class action lawsuits; the loss or insolvency of a major customer or distributor; repeated or prolonged government and/or business shutdowns or similar events; acts of war or terrorism; natural or man-made disasters; water shortages; severe weather conditions; changes in tax laws and unanticipated tax liabilities; potential loss of deferred tax assets; our indebtedness, and any failure to comply with covenants that apply to our indebtedness; potential losses arising from the impairment of goodwill or other assets; and other uncertainties or risks reported from time to time in our reports to the SEC. In light of these risks, uncertainties, assumptions and factors, the forward-looking events discussed in this news release may not occur. We caution that undue reliance should not be placed on forward-looking statements, which speak only as of the date made. Ecolab does not undertake, and expressly disclaims, any duty to update

------

any forward-looking statement whether as a result of new information, future events or changes in expectations, except as required by law.

Non-GAAP Financial Information

This news release and certain of the accompanying tables include financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. ("GAAP").

These non-GAAP financial measures include:

• adjusted net sales

• fixed currency sales

• adjusted fixed currency sales

• acquisition adjusted fixed currency sales

• adjusted cost of sales

● adjusted gross profit

• adjusted gross margin

• fixed currency operating income

• adjusted operating income

• adjusted fixed currency operating income

• adjusted fixed currency operating income margin

• acquisition adjusted fixed currency operating income

• acquisition adjusted fixed currency operating income margin

● adjusted other (income) expense

• adjusted tax rate

• adjusted net income attributable to Ecolab

• adjusted diluted earnings per share

● free cash flow

We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.

Our non-GAAP adjusted financial measure for net sales excludes 2021 Purolite sales. Our non-

------

GAAP adjusted financial measures for cost of sales, gross margin, operating income, other (income) expense and interest expense exclude the impact of special (gains) and charges and (with the exception of other (income) expense) the 2021 impact of the Purolite transaction, and our non-GAAP measures for tax rate, net income attributable to Ecolab and diluted earnings per share further exclude the impact of discrete tax items. We include items within special (gains) and charges and discrete tax items that we believe can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results. After tax special (gains) and charges are derived by applying the applicable local jurisdictional tax rate to the corresponding pre-tax special (gains) and charges.

We evaluate the performance of our international operations based on fixed currency rates of foreign exchange, which eliminate the translation impact of exchange rate fluctuations on our international results. Fixed currency amounts included in this release are based on translation into U.S. dollars at the fixed foreign currency exchange rates established by management at the beginning of 2022. We also provide our segment results based on public currency rates for informational purposes.

Our reportable segments do not include the impact of intangible asset amortization from the Nalco and Purolite transactions or the impact of special (gains) and charges as these are not allocated to the Company's reportable segments.

Acquisition adjusted growth rates exclude the results of our acquired businesses from the first twelve months post acquisition and exclude the results of divested businesses from the twelve months prior to divestiture. Further, we have excluded the results of our Purolite business for all of 2022 to remain comparable to 2021 when Purolite's results were excluded from our adjusted results. In addition, as part of the separation, we also entered into a Master Cross Supply and Product Transfer agreement with ChampionX to provide, receive or transfer certain products for a period up to 36 months. Sales of product to ChampionX under this agreement are recorded in product and equipment sales in the Corporate segment along with the related cost of sales. These transactions are removed from the consolidated results as part of the calculation of the impact of acquisitions and divestitures.

We define free cash flow as net cash provided by operating activities less cash outlays for capital

------

expenditures. It should not be inferred that the entire free cash flow amount is available for discretionary expenditures. It should not be considered a substitute for income or cash flow data prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. We believe free cash flow is meaningful to investors as it functions as a useful measure of performance and we use this measure as an indication of the strength of the Company and its ability to generate cash.

These non-GAAP financial measures are not in accordance with, or an alternative to, GAAP and may be different from non-GAAP measures used by other companies. Investors should not rely on any single financial measure when evaluating our business. We recommend that investors view these measures in conjunction with the GAAP measures included in this news release. Reconciliations of our non-GAAP measures are included in the following "Supplemental Non-GAAP Reconciliations" and "Supplemental Diluted Earnings per Share Information" tables included in this news release.

We do not provide reconciliations for non-GAAP estimates on a forward-looking basis (including those contained in this news release) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of various items that have not yet occurred, are out of our control and/or cannot be reasonably predicted, and that would impact reported earnings per share and the reported tax rate, the most directly comparable forward-looking GAAP financial measures to adjusted earnings per share and the adjusted tax rate. For the same reasons, we are unable to address the probable significance of the unavailable information.

###

(ECL-E)<br>

------

**ECOLAB INC.**

**CONSOLIDATED STATEMENTS OF INCOME**

(unaudited)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | Fourth Quarter Ended | Fourth Quarter Ended |  | Twelve Months Ended  | Twelve Months Ended  |  |
|  | December 31 | December 31 | %  | December 31 | December 31 | %  |
| (millions, except per share) | **2022** | 2021 | Change | **2022** | 2021 | Change |
| &nbsp;&nbsp;Product and equipment sales | **$2972.3** | $2691.7 |  | **$11446.2** | $10153.3 |  |
| &nbsp;&nbsp;Service and lease sales | **698.9** | 672.9 |  | **2741.6** | 2579.8 |  |
| Net sales | **3671.2** | 3364.6 | 9% | **14187.8** | 12733.1 | 11% |
| &nbsp;&nbsp;Product and equipment cost of sales | **1841.1** | 1648.0 |  | **7212.8** | 6100.9 |  |
| &nbsp;&nbsp;Service and lease cost of sales | **413.8** | 395.1 |  | **1618.2** | 1514.9 |  |
| Cost of sales <sup>(1)</sup> | **2254.9** | 2043.1 | 10% | **8831.0** | 7615.8 | 16% |
| &nbsp;&nbsp;Selling, general and administrative expenses | **922.1** | 867.9 | 6% | **3653.8** | 3416.1 | 7% |
| &nbsp;&nbsp;Special (gains) and charges <sup>(1)</sup> | **95.0** | 65.9 |  | **140.5** | 102.6  |  |
| Operating income | **399.2** | 387.7 | 3% | **1562.5** | 1598.6 | (2)% |
| Other (income) expense <sup>(1)</sup> | **8.1**  | (6.4) | (227)% | **(24.5)** | (33.9) | (28)% |
| Interest expense, net <sup>(1)</sup> | **69.5** | 44.6 | 56% | **243.6** | 218.3 | 12% |
| Income before income taxes | **321.6** | 349.5 | (8)% | **1343.4** | 1414.2 | (5)% |
| Provision for income taxes | **52.1** | 44.2 | 18% | **234.5** | 270.2 | (13)% |
| Net income including noncontrolling interest | **269.5** | 305.3 | (12)% | **1108.9** | 1144.0 | (3)% |
| Net income attributable to noncontrolling interest | **5.1** | 4.3 |  | **17.2** | 14.1 |  |
| Net income attributable to Ecolab | **$264.4**  | $301.0  | (12)% | **$1091.7**  | $1129.9  | (3)% |
| Earnings attributable to Ecolab per common share | Earnings attributable to Ecolab per common share |  |  |  |  |  |
| &nbsp;&nbsp;Basic | **$0.93**  | $1.05 | (11)% | **$3.83**  | $3.95 | (3)% |
| &nbsp;&nbsp;Diluted | **$0.93**  | $1.04 | (11)% | **$3.81**  | $3.91 | (3)% |
| Weighted-average common shares outstanding | Weighted-average common shares outstanding |  |  |  |  |  |
| &nbsp;&nbsp;Basic | **284.6** | 286.7 | (1)% | **285.2** | 286.3 | 0% |
| &nbsp;&nbsp;Diluted | **285.8** | 289.5 | (1)% | **286.6** | 289.1 | (1)% |
| (1) Cost of sales, Special (gains) and charges, Other (income) expense and Interest expense, net in the Consolidated Statement of Income above include the following: | (1) Cost of sales, Special (gains) and charges, Other (income) expense and Interest expense, net in the Consolidated Statement of Income above include the following: | (1) Cost of sales, Special (gains) and charges, Other (income) expense and Interest expense, net in the Consolidated Statement of Income above include the following: | (1) Cost of sales, Special (gains) and charges, Other (income) expense and Interest expense, net in the Consolidated Statement of Income above include the following: | (1) Cost of sales, Special (gains) and charges, Other (income) expense and Interest expense, net in the Consolidated Statement of Income above include the following: | (1) Cost of sales, Special (gains) and charges, Other (income) expense and Interest expense, net in the Consolidated Statement of Income above include the following: | (1) Cost of sales, Special (gains) and charges, Other (income) expense and Interest expense, net in the Consolidated Statement of Income above include the following: |
|  | Fourth Quarter Ended | Fourth Quarter Ended |  | Twelve Months Ended  | Twelve Months Ended  |  |
|  | December 31 | December 31 |  | December 31 | December 31 |  |
| (millions) | **2022** | 2021 |  | **2022** | 2021 |  |
| Cost of sales |  |  |  |  |  |  |
| &nbsp;&nbsp;Restructuring activities | **$15.9** | $0.6 |  | **$21.4** | $24.7 |  |
| &nbsp;&nbsp;Acquisition and integration activities | **(7.7)** | 4.2 |  | **25.0** | 4.2 |  |
| &nbsp;&nbsp;COVID-19 activities, net | **-** | 12.9 |  | **16.3** | 64.7 |  |
| &nbsp;&nbsp;Russia/Ukraine activities | **-** | - |  | **7.2** | - |  |
| &nbsp;&nbsp;Other | **-** | - |  | **-** | 0.3 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal <sup>(a)</sup> | **8.2** | 17.7 |  | **69.9** | 93.9 |  |
| Special (gains) and charges |  |  |  |  |  |  |
| &nbsp;&nbsp;Restructuring activities | **85.0** | 5.4 |  | **85.8** | 11.9 |  |
| &nbsp;&nbsp;Acquisition and integration activities | **(0.5)** | 26.6 |  | **14.5** | 29.9 |  |
| &nbsp;&nbsp;COVID-19 activities, net | **3.1** | 26.2 |  | **10.2** | 42.4 |  |
| &nbsp;&nbsp;Russia/Ukraine activities | **-** | - |  | **5.9** | - |  |
| &nbsp;&nbsp;Other | **7.4** | 7.7 |  | **24.1** | 18.4 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal | **95.0** | 65.9 |  | **140.5** | 102.6 |  |
| Interest expense, net | **-** | 0.8 |  | **-** | 33.1 |  |
| Other (income) expense |  |  |  |  |  |  |
| &nbsp;&nbsp;Pension Settlements/Curtailments | **25.8** | 10.6 |  | **50.6** | 37.2 |  |
| Total special (gains) and charges | **$129.0** | $95.0 |  | **$261.0** | $266.8 |  |

---

(a) Special charges of $6.2 million and $17.6 million in the fourth quarter of 2022 and 2021 respectively, and $65.0 million and $91.9 million for the twelve months ended December 31, 2022 and 2021, respectively, were recorded in product and equipment cost of sales. Special charges of $2.0 million and $0.1 million in the fourth quarter of 2022 and 2021, respectively, and $4.9 million and $2.0 million for the twelve months ended December 31, 2022 and 2021 respectively, were recorded in service and lease cost of sales.

------

**ECOLAB INC.**

**REPORTABLE SEGMENT INFORMATION**

(unaudited)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 |
|  | Fixed Currency Rates | Fixed Currency Rates | Fixed Currency Rates | Public Currency Rates | Public Currency Rates | Public Currency Rates |
|  |  |  | % |  |  | % |
| (millions) | **2022** | 2021 | Change | **2022** | 2021 | Change |
| Net Sales |  |  |  |  |  |  |
| &nbsp;&nbsp;Global Industrial | **$1866.2** | $1634.6 | 14% | **$1779.8** | $1659.2 | 7% |
| &nbsp;&nbsp;Global Institutional & Specialty | **1156.6** | 1044.1 | 11% | **1124.6** | 1051.9 | 7% |
| &nbsp;&nbsp;Global Healthcare & Life Sciences | **431.1** | 296.8  | 45% | **400.2** | 300.2  | 33% |
| &nbsp;&nbsp;Other | **354.6** | 315.8  | 12% | **339.2** | 318.2  | 7% |
| &nbsp;&nbsp;Corporate | **27.7** | 34.7  | (20)% | **27.4** | 35.1  | (22)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal at fixed currency rates | **3836.2** | 3326.0 | 15% | **3671.2** | 3364.6 | 9% |
| &nbsp;&nbsp;Currency impact | **(165.0)** | 38.6 | \* | **-** | - | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;Consolidated reported GAAP net sales | **$3671.2** | $3364.6 | 9% | **$3671.2** | $3364.6 | 9% |
| Operating Income (loss) |  |  |  |  |  |  |
| &nbsp;&nbsp;Global Industrial | **$283.8** | $266.0 | 7% | **$267.6** | $272.1 | (2)% |
| &nbsp;&nbsp;Global Institutional & Specialty | **172.0** | 155.2  | 11% | **165.5** | 157.0  | 5% |
| &nbsp;&nbsp;Global Healthcare & Life Sciences | **67.7** | 28.4  | 138% | **61.0** | 29.0  | 110% |
| &nbsp;&nbsp;Other | **59.2** | 43.1  | 37% | **56.0** | 43.5  | 29% |
| &nbsp;&nbsp;Corporate | **(152.0)** | (113.8) | \* | **(150.9)** | (113.9) | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal at fixed currency rates | **430.7** | 378.9 | 14% | **399.2** | 387.7 | 3% |
| &nbsp;&nbsp;Currency impact | **(31.5)** | 8.8 | \* | **-** | - | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;Consolidated reported GAAP operating income | **$399.2** | $387.7 | 3% | **$399.2** | $387.7 | 3% |
|  | Year Ended December 31 | Year Ended December 31 | Year Ended December 31 | Year Ended December 31 | Year Ended December 31 | Year Ended December 31 |
|  | Fixed Currency Rates | Fixed Currency Rates | Fixed Currency Rates | Public Currency Rates | Public Currency Rates | Public Currency Rates |
|  |  |  | % |  |  | % |
| (millions) | **2022** | 2021 | Change | **2022** | 2021 | Change |
| Net Sales |  |  |  |  |  |  |
| &nbsp;&nbsp;Global Industrial | **$6944.0** | $6086.8 | 14% | **$6805.0** | $6237.8 | 9% |
| &nbsp;&nbsp;Global Institutional & Specialty | **4480.0** | 3908.8 | 15% | **4421.9** | 3955.9 | 12% |
| &nbsp;&nbsp;Global Healthcare & Life Sciences | **1570.0** | 1149.6 | 37% | **1510.5** | 1181.6 | 28% |
| &nbsp;&nbsp;Other | **1355.0** | 1201.0 | 13% | **1326.6** | 1218.6 | 9% |
| &nbsp;&nbsp;Corporate | **124.1** | 137.4 | (10)% | **123.8** | 139.2 | (11)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal at fixed currency rates | **14473.1** | 12483.6 | 16% | **14187.8** | 12733.1 | 11% |
| &nbsp;&nbsp;Currency impact | **(285.3)** | 249.5  | \* | **-** | - | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;Consolidated reported GAAP net sales | **$14187.8** | $12733.1 | 11% | **$14187.8** | $12733.1 | 11% |
| Operating Income |  |  |  |  |  |  |
| &nbsp;&nbsp;Global Industrial | **$977.0** | $985.7 | (1)% | **$951.8** | $1020.3 | (7)% |
| &nbsp;&nbsp;Global Institutional & Specialty | **634.5** | 545.7 | 16% | **624.0** | 550.9 | 13% |
| &nbsp;&nbsp;Global Healthcare & Life Sciences | **205.0** | 152.3 | 35% | **193.4** | 158.4 | 22% |
| &nbsp;&nbsp;Other | **212.8** | 184.0 | 16% | **208.1** | 186.8 | 11% |
| &nbsp;&nbsp;Corporate | **(416.7)** | (316.6) | \* | **(414.8)** | (317.8) | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal at fixed currency rates | **1612.6** | 1551.1 | 4% | **1562.5** | 1598.6 | (2)% |
| &nbsp;&nbsp;Currency impact | **(50.1)** | 47.5  | \* | **-** | - | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;Consolidated reported GAAP operating income | **$1562.5** | $1598.6 | (2)% | **$1562.5** | $1598.6 | (2)% |

---

\* Not meaningful.

As shown in the "Fixed Currency Rates" tables above, we evaluate the performance of our international operations based on fixed currency exchange rates, which eliminate the impact of exchange rate fluctuations on our international operations. Amounts shown in the "Public Currency Rates" tables above reflect amounts translated at actual public average rates of exchange prevailing during the corresponding period and are provided for informational purposes. The difference between the fixed currency exchange rates and the public currency exchange rates is reported as "Currency impact" in the "Fixed Currency Rates" tables above.

The Corporate segment includes amortization from the Nalco and Purolite transactions intangible assets. The Corporate segment also includes special (gains) and charges reported on the Consolidated Statement of Income.

------

**ECOLAB INC.**

**CONSOLIDATED BALANCE SHEETS**

(unaudited)

---

| | | |
|:---|:---|:---|
|  | **December 31** | December 31 |
| (millions) | **2022** | 2021 |
| Assets |  |  |
| Current assets |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | **$598.6** | $359.9 |
| &nbsp;&nbsp;Accounts receivable, net | **2698.1** | 2478.4 |
| &nbsp;&nbsp;Inventories | **1792.8** | 1491.8 |
| &nbsp;&nbsp;Other current assets | **404.7** | 357.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current assets | **5494.2** | 4687.1 |
| &nbsp;&nbsp;Property, plant and equipment, net | **3293.4** | 3288.5 |
| &nbsp;&nbsp;Goodwill | **8012.7** | 8063.9 |
| &nbsp;&nbsp;Other intangible assets, net | **3680.7** | 4224.1 |
| &nbsp;&nbsp;Operating lease assets | **448.2** | 396.8 |
| &nbsp;&nbsp;Other assets | **535.1** | 546.0 |
| Total assets | **$21464.3** | $21206.4 |
| Liabilities and Equity |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;Short-term debt | **$505.1** | $411.0 |
| &nbsp;&nbsp;Accounts payable | **1728.2** | 1384.2 |
| &nbsp;&nbsp;Compensation and benefits | **493.6** | 509.5 |
| &nbsp;&nbsp;Income taxes | **197.6** | 104.3 |
| &nbsp;&nbsp;Other current liabilities | **1285.9** | 1144.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | **4210.4** | 3553.2 |
| &nbsp;&nbsp;Long-term debt | **8075.3** | 8347.2 |
| &nbsp;&nbsp;Postretirement health care and pension benefits | **670.3** | 894.2 |
| &nbsp;&nbsp;Deferred income taxes | **505.6** | 622.0 |
| &nbsp;&nbsp;Operating lease liabilities | **337.8** | 282.6 |
| &nbsp;&nbsp;Other liabilities | **406.3** | 254.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | **14205.7** | 13953.3 |
| Equity |  |  |
| &nbsp;&nbsp;Common stock | **364.7** | 364.1 |
| &nbsp;&nbsp;Additional paid-in capital | **6580.2** | 6464.6 |
| &nbsp;&nbsp;Retained earnings | **9318.8** | 8814.5 |
| &nbsp;&nbsp;Accumulated other comprehensive loss | **(1726.6)** | (1634.8) |
| &nbsp;&nbsp;Treasury stock | **(7301.0)** | (6784.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Ecolab shareholders' equity | **7236.1** | 7224.2 |
| &nbsp;&nbsp;Noncontrolling interest | **22.5** | 28.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total equity | **7258.6** | 7253.1 |
| Total liabilities and equity | **$21464.3** | $21206.4 |

---

------

**ECOLAB INC.**

**SUPPLEMENTAL NON-GAAP RECONCILIATIONS**

(unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Fourth Quarter Ended | Fourth Quarter Ended | Twelve Months Ended  | Twelve Months Ended  |
|  | December 31 | December 31 | December 31 | December 31 |
| (millions, except percent and per share) | **2022** | 2021 | **2022** | 2021 |
| Net sales |  |  |  |  |
| &nbsp;&nbsp;Reported GAAP net sales | **$3671.2** | $3364.6 | **$14187.8** | $12733.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;2021 impact of Purolite on net sales | **-** | 12.0  | **-** | 12.0  |
| &nbsp;&nbsp;Non-GAAP adjusted net sales | **3671.2** | 3352.6  | **14187.8** | 12721.1  |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of foreign currency translation | **165.0**  | (38.6) | **285.3**  | (249.5) |
| &nbsp;&nbsp;Non-GAAP adjusted fixed currency sales | **3836.2** | 3314.0 | **14473.1** | 12471.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of acquisitions and divestitures | **(155.1)** | (34.7) | **(580.0)** | (137.4) |
| &nbsp;&nbsp;Non-GAAP acquisition adjusted fixed currency sales | **$3681.1** | $3279.3 | **$13893.1** | $12334.2 |
| Cost of sales |  |  |  |  |
| &nbsp;&nbsp;Reported GAAP cost of sales | **$2254.9** | $2043.1 | **$8831.0** | $7615.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Special (gains) and charges | **8.2** | 17.7  | **69.9** | 93.9  |
| &nbsp;&nbsp;&nbsp;&nbsp;2021 impact of Purolite on cost of sales | **-** | 7.6  | **-** | 7.6  |
| &nbsp;&nbsp;Non-GAAP adjusted cost of sales | **$2246.7** | $2017.8 | **$8761.1** | $7514.3 |
| Gross profit |  |  |  |  |
| &nbsp;&nbsp;Reported GAAP gross profit  | **$1416.3** | $1321.5 | **$5356.8** | $5117.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Special (gains) and charges | **8.2** | 17.7 | **69.9** | 93.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;2021 impact of Purolite on gross profit | **-** | 4.4 | **-** | 4.4 |
| &nbsp;&nbsp;Non-GAAP adjusted gross profit | **$1424.5** | $1334.8 | **$5426.7** | $5206.8 |
| Gross margin |  |  |  |  |
| &nbsp;&nbsp;Reported GAAP gross margin | **38.6%** | 39.3% | **37.8%** | 40.2% |
| &nbsp;&nbsp;Non-GAAP adjusted gross margin | **38.8%** | 39.8% | **38.2%** | 40.9% |
| Operating income |  |  |  |  |
| &nbsp;&nbsp;Reported GAAP operating income | **$399.2** | $387.7 | **$1562.5** | $1598.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of foreign currency translation | **31.5**  | (8.8) | **50.1**  | (47.5) |
| &nbsp;&nbsp;Non-GAAP fixed currency operating income | **430.7**  | 378.9 | **1612.6** | 1551.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Special (gains) and charges | **103.2**  | 83.6  | **210.4**  | 196.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;2021 impact of Purolite on operating income | **-** | 3.8  | **-** | 3.8 |
| &nbsp;&nbsp;Non-GAAP adjusted fixed currency operating income | **533.9** | 466.3 | **1823.0** | 1751.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of acquisitions and divestitures | **(22.6)** | - | **(23.1)** | - |
| &nbsp;&nbsp;Non-GAAP acquisition adjusted fixed currency operating income | **$511.3** | $466.3 | **$1799.9** | $1751.4 |
| Operating income margin |  |  |  |  |
| &nbsp;&nbsp;Reported GAAP operating income margin | **10.9%** | 11.5% | **11.0%** | 12.6% |
| &nbsp;&nbsp;Non-GAAP adjusted fixed currency operating income margin | **13.9%** | 14.1% | **12.6%** | 14.0% |
| &nbsp;&nbsp;Non-GAAP acquisition adjusted fixed currency operating income margin | **13.9%** | 14.2% | **13.0%** | 14.2% |

---

------

**ECOLAB INC.**

**SUPPLEMENTAL NON-GAAP RECONCILIATIONS**

(unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Fourth Quarter Ended | Fourth Quarter Ended | Twelve Months Ended  | Twelve Months Ended  |
|  | December 31 | December 31 | December 31 | December 31 |
| (millions, except percent and per share) | **2022** | 2021 | **2022** | 2021 |
| Other (income) expense |  |  |  |  |
| &nbsp;&nbsp;Reported GAAP other (income) expense | **$8.1**  | ($6.4) | **($24.5)** | ($33.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Special (gains) and charges | **25.8** | 10.6 | **50.6**  | 37.2 |
| &nbsp;&nbsp;Non-GAAP adjusted other (income) expense | **($17.7)** | ($17.0) | **($75.1)** | ($71.1) |
| Interest expense, net |  |  |  |  |
| &nbsp;&nbsp;Reported GAAP interest expense, net | **$69.5** | $44.6 | **$243.6** | $218.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Special (gains) and charges | **-** | 0.8 | **-** | 33.1  |
| &nbsp;&nbsp;&nbsp;&nbsp;2021 impact of Purolite on interest expense, net | **-** | 3.5 | **-** | 3.5  |
| &nbsp;&nbsp;Non-GAAP adjusted interest expense, net | **$69.5** | $40.3 | **$243.6** | $181.7 |
| Net Income attributable to Ecolab |  |  |  |  |
| &nbsp;&nbsp;Reported GAAP net income attributable to Ecolab | **$264.4** | $301.0 | **$1091.7** | $1129.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Special (gains) and charges, after tax | **101.5**  | 74.4  | **207.3**  | 213.5  |
| &nbsp;&nbsp;&nbsp;&nbsp;Discrete tax net expense (benefit) | **(2.3)** | (11.7) | **(11.8)** | 5.8  |
| &nbsp;&nbsp;&nbsp;&nbsp;2021 impact of Purolite on net income | **-** | 5.6  | **-** | 5.6  |
| &nbsp;&nbsp;Non-GAAP adjusted net income attributable to Ecolab | **$363.6** | $369.3 | **$1287.2** | $1354.8 |
| Diluted EPS attributable to Ecolab |  |  |  |  |
| &nbsp;&nbsp;Reported GAAP diluted EPS | **$0.93** | $1.04 | **$3.81** | $3.91 |
| &nbsp;&nbsp;&nbsp;&nbsp;Special (gains) and charges, after tax | **0.35**  | 0.26  | **0.72**  | 0.74  |
| &nbsp;&nbsp;&nbsp;&nbsp;Discrete tax net expense (benefit) | **(0.01)** | (0.04) | **(0.04)** | 0.02  |
| &nbsp;&nbsp;&nbsp;&nbsp;2021 impact of Purolite on diluted EPS | **-** | 0.02  | **-** | 0.02  |
| &nbsp;&nbsp;Non-GAAP adjusted diluted EPS | **$1.27** | $1.28 | **$4.49** | $4.69 |
| Provision for Income Taxes |  |  |  |  |
| &nbsp;&nbsp;Reported GAAP tax rate | **16.2%** | 12.6% | **17.5%** | 19.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;Special gains and charges | **1.5**  | 2.0 | **0.5**  | 0.1  |
| &nbsp;&nbsp;&nbsp;&nbsp;Discrete tax items | **0.5**  | 2.6  | **0.7**  | (0.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;2021 Purolite tax impacts | **-** | 0.1  | **-** | - |
| &nbsp;&nbsp;Non-GAAP adjusted tax rate | 18.2<br>**%** | 17.3% | 18.7<br>**%** | 18.9% |

---

------

**ECOLAB INC.**

**SUPPLEMENTAL NON-GAAP RECONCILIATIONS**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 | Fourth Quarter Ended December 31 |
| (unaudited) | **2022** | **2022** | **2022** | 2021 | 2021 | 2021 |
| (millions) | Fixed Currency | Impact of Acquisitions and Divestitures | Acquisition Adjusted | Fixed Currency | Impact of Acquisitions and Divestitures | Acquisition Adjusted |
| Net Sales |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Global Industrial | **$1866.2** | **$0.0**  | **$1866.2** | $1634.6 | $0.0  | $1634.6 |
| &nbsp;&nbsp;&nbsp;Global Institutional & Specialty | **1156.6** | **-** | **1156.6** | 1044.1 | - | 1044.1 |
| &nbsp;&nbsp;&nbsp;Global Healthcare & Life Sciences | **431.1** | **(127.4)** | **303.7** | 296.8 | (12.0) | 284.8 |
| &nbsp;&nbsp;&nbsp;Other | **354.6** | **-** | **354.6** | 315.8 | - | 315.8 |
| &nbsp;&nbsp;&nbsp;Corporate | **27.7** | **(27.7)** | **-** | 34.7 | (34.7) | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subtotal at fixed currency rates | **3836.2** | **(155.1)** | **3681.1** | 3326.0 | (46.7) | 3279.3 |
| &nbsp;&nbsp;&nbsp;Currency impact | **(165.0)** |  |  | 38.6 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated reported GAAP net sales | **$3671.2** |  |  | $3364.6 |  |  |
| Operating Income (loss) |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Global Industrial | **$283.8** | **$0.0**  | **$283.8** | $266.0 | $0.0  | $266.0 |
| &nbsp;&nbsp;&nbsp;Global Institutional & Specialty | **172.0** | **-** | **172.0** | 155.2 | - | 155.2 |
| &nbsp;&nbsp;&nbsp;Global Healthcare & Life Sciences | **67.7** | **(41.2)** | **26.5** | 28.4 | 3.8 | 32.2 |
| &nbsp;&nbsp;&nbsp;Other | **59.2** | **-** | **59.2** | 43.1 | - | 43.1 |
| &nbsp;&nbsp;&nbsp;Corporate | **(48.8)** | **18.6** | **(30.2)** | (30.2) | - | (30.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subtotal at fixed currency rates | **533.9** | **(22.6)** | **511.3** | 462.5 | 3.8 | 466.3 |
| &nbsp;&nbsp;&nbsp;Special (gains) and charges | **103.2** |  |  | 83.6 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reported OI at fixed currency rates | **430.7** |  |  | 378.9 |  |  |
| &nbsp;&nbsp;&nbsp;Currency impact | **(31.5)** |  |  | 8.8 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated reported GAAP operating income | **$399.2** |  |  | $387.7 |  |  |
|  | Year Ended December 31 | Year Ended December 31 | Year Ended December 31 | Year Ended December 31 | Year Ended December 31 | Year Ended December 31 |
|  | **2022** | **2022** | **2022** | 2021 | 2021 | 2021 |
| (millions) | Fixed Currency | Impact of Acquisitions and Divestitures | Acquisition Adjusted | Fixed Currency | Impact of Acquisitions and Divestitures | Acquisition Adjusted |
| Net Sales |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Global Industrial | **$6944.0** | **($21.0)** | **$6923.0** | $6086.8 | $0.0  | $6086.8 |
| &nbsp;&nbsp;&nbsp;Global Institutional & Specialty | **4480.0** | **-** | **4480.0** | 3908.8 | - | 3908.8 |
| &nbsp;&nbsp;&nbsp;Global Healthcare & Life Sciences | **1570.0** | **(434.9)** | **1135.1** | 1149.6 | (12.0) | 1137.6 |
| &nbsp;&nbsp;&nbsp;Other | **1355.0** | **-** | **1355.0** | 1201.0 | - | 1201.0 |
| &nbsp;&nbsp;&nbsp;Corporate | **124.1** | **(124.1)** | **-** | 137.4 | (137.4) | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subtotal at fixed currency rates | **14473.1** | **(580.0)** | **13893.1** | 12483.6 | (149.4) | 12334.2 |
| &nbsp;&nbsp;&nbsp;Currency impact | **(285.3)** |  |  | 249.5 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated reported GAAP net sales | **$14187.8** |  |  | $12733.1 |  |  |
| Operating Income (loss) |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Global Industrial | **$977.0** | **($3.4)** | **$973.6** | $985.7 | $0.0  | $985.7 |
| &nbsp;&nbsp;&nbsp;Global Institutional & Specialty | **634.5** | **-** | **634.5** | 545.7 | - | 545.7 |
| &nbsp;&nbsp;&nbsp;Global Healthcare & Life Sciences | **205.0** | **(106.3)** | **98.7** | 152.3 | 3.8 | 156.1 |
| &nbsp;&nbsp;&nbsp;Other | **212.8** | **-** | **212.8** | 184.0 | - | 184.0 |
| &nbsp;&nbsp;&nbsp;Corporate | **(206.3)** | **86.6** | **(119.7)** | (120.1) | - | (120.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subtotal at fixed currency rates | **1823.0** | **(23.1)** | **1799.9** | 1747.6 | 3.8 | 1751.4 |
| &nbsp;&nbsp;&nbsp;Special (gains) and charges | **210.4** |  |  | 196.5 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reported OI at fixed currency rates | **1612.6** |  |  | 1551.1 |  |  |
| &nbsp;&nbsp;&nbsp;Currency impact | **(50.1)** |  |  | 47.5 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated reported GAAP operating income | **$1562.5** |  |  | $1598.6 |  |  |

---

------

**ECOLAB INC.**

**SUPPLEMENTAL NON-GAAP RECONCILIATIONS**

(unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
| Selected Cash Flow items | Fourth Quarter Ended | Fourth Quarter Ended | Twelve Months Ended  | Twelve Months Ended  |
|  | December 31 | December 31 | December 31 | December 31 |
| (millions) | **2022** | **2021** | **2022** | **2021** |
| Cash provided by operating activities | **$859.2** | $640.9 | **$1788.4** | $2061.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: Capital expenditures | **(202.8)** | (219.2) | **(712.8)** | (643.0) |
| Free cash flow | **$656.4** | $421.7 | **$1075.6** | $1418.9 |

---

------

**ECOLAB INC.**

**SUPPLEMENTAL DILUTED EARNINGS PER SHARE INFORMATION**

(unaudited)

The table below provides a reconciliation of diluted earnings per share, as reported, to the non-GAAP measure of adjusted diluted earnings per share.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | First<br>Quarter<br>Ended<br>Mar. 31<br>2021 | Second<br>Quarter<br>Ended<br>June 30<br>2021 | Six<br>Months<br>Ended<br>June 30<br>2021 | Third<br>Quarter<br>Ended<br>Sept. 30<br>2021 | Nine<br>Months<br>Ended<br>Sept. 30<br>2021 | Fourth<br>Quarter<br>Ended<br>Dec. 31<br>2021 | &nbsp;&nbsp;&nbsp;&nbsp;<br>Year<br>Ended<br>Dec. 31<br>2021 |
| Diluted earnings per share, as reported (U.S. GAAP) | $0.67 | $1.08 | $1.75 | $1.12 | $2.87 | $1.04 | $3.91 |
| Adjustments: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Special (gains) and charges <sup>(1)</sup> | 0.08  | 0.12  | 0.20  | 0.28  | 0.48  | 0.26  | 0.74  |
| &nbsp;&nbsp;Discrete tax expense (benefits) <sup>(2)</sup> | 0.06  | 0.02  | 0.08  | (0.02) | 0.06  | (0.04) | 0.02  |
| &nbsp;&nbsp;Impact of Purolite on diluted earnings per share |  |  |  |  |  | 0.02  | 0.02  |
| Adjusted diluted earnings per share (Non-GAAP) | $0.81 | $1.22 | $2.03 | $1.38 | $3.41 | $1.28 | $4.69 |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | First<br>Quarter<br>Ended<br>Mar. 31<br>2022 | Second<br>Quarter<br>Ended<br>June 30<br>2022 | Six<br>Months<br>Ended<br>June 30<br>2022 | Third<br>Quarter<br>Ended<br>Sept. 30<br>2022 | Nine<br>Months<br>Ended<br>Sept. 30<br>2022 | Fourth<br>Quarter<br>Ended<br>Dec. 31<br>2022 | &nbsp;&nbsp;&nbsp;&nbsp;<br>Year<br>Ended<br>Dec. 31<br>2022 |
| Diluted earnings per share, as reported (U.S. GAAP) | **$0.60** | **$1.08**  | **$1.67** | **$1.21** | **$2.88** | **$0.93** | **$3.81** |
| Adjustments: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Special (gains) and charges <sup>(3)</sup> | **0.22**  | **0.01**  | **0.23**  | **0.14**  | **0.37**  | **0.35**  | **0.72**  |
| &nbsp;&nbsp;Discrete tax expense (benefits) <sup>(4)</sup> | **0.00**  | **0.01**  | **0.02**  | **(0.05)** | **(0.03)** | **(0.01)** | **(0.04)** |
| Adjusted diluted earnings per share (Non-GAAP) | **$0.82** | **$1.10** | **$1.92** | **$1.30** | **$3.22** | **$1.27** | **$4.49** |

---

Per share amounts do not necessarily sum due to changes in shares outstanding and rounding.

(1) Special (gains) and charges for 2021 includes charges of $24.2 million, $34.1 million, $80.8 million and $74.4 million, net of tax, in the first, second, third and fourth quarters, respectively. Charges include COVID-19 related inventory write downs and employee-related costs (net of government subsidies), restructuring charges, debt refinancing charges, acquisition and integration charges, and litigation and other charges.

(2) Discrete tax expenses (benefits) for 2021 includes $16.1 million, $7.7 million, ($6.3) million and ($11.7) million in the first, second, third and fourth quarters, respectively. These expenses (benefits) are primarily associated with stock compensation excess tax benefits more than offset by other discrete tax expense.

(3) Special (gains) and charges for 2022 includes charges of $63.6 million, $2.6 million, $39.6 million and $101.5 million, net of tax, in the first, second, third and fourth quarters, respectively. Charges include acquisition and integration charges, reserves related to our operations in Russia, COVID-19 related inventory write downs and employee-related costs, restructuring charges, litigation and other charges and pension settlements.

(4) Discrete tax expenses (benefits) for 2022 includes $1.0 million, $3.7 million, ($14.2) million and ($2.3) million in the first, second, third and fourth quarters, respectively. These expenses (benefits) are primarily associated with stock compensation excess tax benefits and other discrete tax benefits.

------

## Exhibit 99.2

#### Exhibit 99.2

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g001.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fourth Quarter 2022 Supplemental 1 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g002.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cautionary Statement Forward-Looking Information This communication contains forward looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding global economic conditions, delivered products costs, demand, inflation, currency translation, interest and pension expense, our financial and business performance and prospects, including sales, earnings, pricing, margins, new business, productivity, restructuring charges and additional capacity. These statements are based on the current expectations of management. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this communication. In particular, the ultimate results of any restructuring initiative depend on a number of factors, including the development of final plans, the impact of local regulatory requirements regarding employee terminations, the time necessary to develop and implement the restructuring initiative and the level of success achieved through such actions in improving competitiveness, efficiency and effectiveness. Additional risks and uncertainties are set forth under Item 1A of our most recent Form 10-K, and our other public filings with the Securities and Exchange Commission ("SEC"), and include the impact of economic factors such as the worldwide economy, capital flows, interest rates, foreign currency risk, reduced sales and earnings in our international operations resulting from the weakening of local currencies versus the U.S. dollar, demand uncertainty, supply chain challenges and inflation; the vitality of the markets we serve; exposure to global economic, political and legal risks related to our international operations, including geopolitical instability, the impact of sanctions or other actions taken by the U.S. or other countries, and retaliatory measures taken by Russia in response, in connection with the conflict in Ukraine; difficulty in procuring raw materials or fluctuations in raw material costs; our ability to attract, retain and develop high caliber management talent to lead our business and successfully execute organizational change and changing labor market dynamics; information technology infrastructure failures or breaches in data security; the effects and duration of the COVID-19 pandemic or other public health outbreaks, epidemics or pandemics; our ability to acquire complementary businesses and to effectively integrate such businesses, including Purolite; and other uncertainties or risks reported from time to time in our reports to the SEC. In light of these risks, uncertainties and factors, the forward-looking events discussed in this communication may not occur. We caution that undue reliance should not be placed on forward-looking statements, which speak only as of the date made. Ecolab does not undertake, and expressly disclaims, any duty to update any forward-looking statement, except as required by law. Non-GAAP Financial Information This communication includes Company information that does not conform to generally accepted accounting principles (GAAP). Management believes that a presentation of this information is meaningful to investors because it provides insight with respect to ongoing operating results of the Company and allows investors to better evaluate the financial results of the Company. These measures should not be viewed as an alternative to GAAP measures of performance. Furthermore, these measures may not be consistent with similar measures provided by other companies. Reconciliations of our non-GAAP measures included within this presentation are included in the "Non-GAAP Financial Measures" section of this presentation. |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g003.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4Q as expected with strong operating performance Continued strong sales growth Positive OI growth with organic OI growth accelerating to double-digits Expect a strong performance in 2023 with further sequential improvement Expanded cost savings program, focused on Institutional and Healthcare ▪ Reported sales +9%, organic sales +12% ▪ Led by Industrial +14%, Institutional & Specialty +11%, and Other segment sales +12% ▪ Healthcare & Life Sciences segment sales growth improved to +7% ▪ Reported OI +3%, organic OI +10% ▪ Pricing +13%, exceeded substantial delivered product costs with net benefit expanding versus 3Q ▪ Significant easing in organic OI margin pressure ▪ Expect to realize $175 million of annualized savings by the end of 2024 (increase from $80 million previously) ▪ Institutional: repositioning to win in the new environment ▪ Healthcare: return to profitable growth ▪ Driving new business, innovation, customer value, and pricing to support strong topline growth and double-digit organic OI growth ▪ Expect quarterly adjusted earnings per share growth to accelerate towards our low double-digit historical performance ▪ Expect first quarter 2023 adjusted diluted earnings per share in the $0.82 to $0.90 range, compared with adjusted diluted earnings per share of $0.82 a year ago 3 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g004.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4Q Overview ▪ Sales growth remained very strong with reported sales +9% and acquisition adjusted fixed currency sales +12% o Total pricing +13% o As expected, volume & mix -1% due to softening demand, particularly in Europe ▪ Double-digit acquisition adjusted fixed currency growth in Institutional & Specialty, Industrial, and Other segments o Industrial +14% o Institutional & Specialty +11% o Healthcare and Life Sciences +7% o Other +12% ▪ Reported diluted EPS $0.93, -11% ▪ Adjusted diluted EPS $1.27, -1% o The expected narrowing decline in earnings reflected continued strong sales growth, including accelerating pricing in excess of delivered product costs and further new business wins. This, along with enhanced productivity drove a 14% increase in adjusted fixed currency operating income, which largely offset significantly unfavorable currency translation and higher interest expense. Sales EPS 4 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g005.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2023 and 1Q Outlook 2023 1Q ▪ We enter 2023 from a position of strength and continue to expect to deliver performance that improves despite a challenging macro environment characterized by high delivered product costs and easing demand. In addition, higher interest expense and currency translation are estimated to have a combined $0.30 per share unfavorable impact in 2023, or a 7% headwind to year-over-year earnings growth. ▪ We expect double-digit growth in adjusted operating income, driven by continued robust sales growth, easing delivered product cost inflation, and improved productivity. This strong performance is expected to more than overcome the challenging environment to deliver quarterly adjusted earnings per share growth that accelerates towards our low double-digit historical performance. ▪ Ecolab expects first quarter 2023 adjusted diluted earnings per share in the $0.82 to $0.90 range, compared with adjusted diluted earnings per share of $0.82 a year ago ▪ This forecast includes an estimated unfavorable $0.13 per share impact from higher interest expense and currency, or a 15% headwind to year-over-year earnings growth ▪ Ecolab currently expects quantifiable special charges in the first quarter of 2023 to be approximately $0.15 per share, principally related to restructuring charges. Other than the special gains and charges noted above, other such amounts are not currently quantifiable. 5 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g006.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Estimated EPS Impact From Interest and Currency 6 (1) See slide 5 for special gains and charges expectations (2) 1Q 23 selected non-operating items represent estimated year-over-year impact to EPS from interest and currency 1Q 23 Forecast EPS YoY % Organic OI1 15% - 25% Selected Non-Operating Items2 Interest ($0.07) (9%) Currency ($0.06) (7%) Total ($0.13) (15%) Adjusted Diluted EPS1 $0.82 - $0.90 0% - 10% |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g007.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4Q 2022 Sales Growth Detail Amounts in the tables above may reflect rounding. Acq. Adj. excludes sales to ChampionX post-separation. 7 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g008.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Global Industrial Segment – Water and Food & Beverage Food & Beverage All sales figures are acquisition adjusted fixed currency unless otherwise noted 8 Sales +14% Sales +17% Water Q1: Expect continued robust sales growth driven by strong pricing and new business wins ▪ Robust sales growth driven by strong pricing and new business wins o Light Water: strong sales driven by double-digit growth across data centers and microelectronics, food & beverage, and manufacturing o Heavy Industry: strong sales led by double-digit gains in power and primary metals o Mining: very strong growth, benefiting from our strategic shift toward high-value metals and fertilizers and away from coal ▪ We continue to drive strong new business wins, led by our innovative chemistry solutions, digital technologies and service expertise that help our customers reduce water consumption toward net zero and meet their sustainability objectives ▪ The impact of increasing water demand, its growing quality and availability issues and the resulting rising costs continue to be a critical issue for our customers, and one that Ecolab is uniquely positioned to help them solve through innovative programs such as Ecolab Water for Climate ▪ Strong sales growth driven by accelerating pricing ▪ Double-digit growth improved across all end markets, led by very strong sales in dairy and food ▪ Sales growth was strong across all regions Q1: Anticipate continued strong sales growth led by robust pricing |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g009.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Global Industrial Segment – Downstream and Paper Downstream Paper All sales figures are acquisition adjusted fixed currency unless otherwise noted 9 Sales +8% Sales +13% Q1: Expect continued robust sales growth as strong pricing and new business wins more than offset comparisons to strong additive sales in the prior year ▪ Robust sales growth driven by strong pricing and good new business wins, somewhat offset by comparisons to strong additive sales in the prior year ▪ Growth was led by very strong petrochemical sales. Regionally, sales grew double-digits in Europe, North America showed solid growth, Asia Pacific was stable, and Latin America declined modestly. ▪ Continued to benefit from our unique technologies that help customers improve the sustainability of their operations while also helping them expand into renewable growth areas Q1: Expect continued robust sales growth as further strong pricing and new business wins more than offsets easing customer production rates ▪ Another quarter of strong sales growth driven by robust pricing and new business wins, somewhat offset by easing customer production rates ▪ Tissue showed very strong growth, driven by strong pricing and new business gains. Graphics also showed strong growth, benefiting from pricing. Growth in board and packaging moderated as strong pricing was offset by easing customer production rates. ▪ Regionally, North America, Europe, Asia Pacific and Latin America grew by double-digits |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g010.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Global Institutional & Specialty Segment Institutional Specialty All sales figures are acquisition adjusted fixed currency unless otherwise noted 10 Sales +11% Sales +9% ▪ Strong sales growth driven by accelerating pricing and new business wins, which together continue to benefit from our innovative products and services that help customers reduce costs in the current inflationary environment and challenging labor market o North America: strong growth driven by accelerating pricing and further new business wins o Europe: strong growth driven by accelerating pricing o Latin America: very strong growth benefiting from increased consumer traffic and new business wins o Asia Pacific: strong growth as softer trends in China due to COVID restrictions were more than offset by robust gains in other parts of the region ▪ Institutional is focused on capitalizing on its attractive growth opportunities, maximizing service effectiveness, and leveraging investments in digital technology to further improve productivity. We expect these enhancements, along with our innovative chemistry and digital programs, which save customers time and money, will support further strong new business generation while also optimizing our cost structure for the current environment. Q1: Expect strong sales driven by further pricing and new business wins Q1: Expect sales to show continued strong growth benefiting from strong pricing, new customer wins, and our broad range of innovative products ▪ Overall sales driven by strong quick service sales and modest growth in food retail sales o Quick service: strong sales reflected accelerating pricing, robust international gains, and new business wins, which more than offset mixed end market trends in the U.S. o Food retail: sales grew modestly reflecting accelerating pricing and good new business wins, though customer labor shortages continued to impact in-store services and associated cleaning and sanitizing product usage |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g011.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Global Healthcare & Life Sciences Segment Healthcare Life Sciences All sales figures are acquisition adjusted fixed currency unless otherwise noted Q1: Expect modest sales growth reflecting continued good pricing 11 Sales +5% Sales +18% ▪ As expected, sales growth improved reflecting accelerated pricing and better surgical sales growth ▪ We are committed to repositioning our healthcare business for profitable growth. Our new business efforts are focused on attractive long-term growth opportunities in the surgical, environmental hygiene, and instrument reprocessing areas, where our leading product lines, ongoing innovation, and digital technologies make us uniquely positioned to help improve patient outcomes while also increasing operational efficiencies for our customers. ▪ Reported sales growth of 169% reflected the acquisition of Purolite. Acquisition adjusted sales growth accelerated to 18%. o Legacy Life Sciences: double-digit sales growth reflected accelerating pricing and growth in consumable pharmaceutical and personal care products, somewhat offset by normalizing demand for Bioquell's biodecontamination systems o Purolite: as expected, sales growth showed a strong acceleration, benefiting from our new capacity additions. Purolite's robust sales growth was led by very strong bioprocessing sales. ▪ We continue to leverage Ecolab's global capabilities and technical expertise in cleaning and sanitizing with Purolite's innovative purification technology to capture the strong customer demand in this rapidly growing market Q1: Expect continued strong sales growth driven by pricing, new business wins, and further benefits from Purolite's capacity additions |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g012.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Segment Pest Elimination All sales figures are acquisition adjusted fixed currency unless otherwise noted 12 Sales +10% ▪ Led by strong growth across food retail, restaurants, hospitality, and food & beverage o Growth benefited from accelerating pricing and continued robust new business wins, driven by our high service levels and innovation ▪ Regionally, North America delivered double-digit growth, Europe showed solid growth, and growth was modest for Latin America and Asia Pacific Q1: Expect continued strong growth, benefiting from additional pricing, new customer wins as we leverage our ongoing innovation, and enhanced digital offerings to further extend our competitive advantages |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g013.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated Margin Performance ▪ Accelerating pricing was more than offset by a significant increase in delivered product costs inflation and unfavorable mix ▪ Year-over-year decline in adjusted gross margin continued to ease sequentially ▪ Improvement driven by sales leverage that more than offset investments in the business ▪ Accelerating pricing overcame substantially higher delivered product costs, investments in the business, and unfavorable mix ▪ Year-over-year decline in acquisition adjusted fixed currency operating income margin continued to ease sequentially Gross Margin SG&A Operating Income 13 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g014.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Segment Operating Income Performance ▪ Acquisition adjusted fixed currency operating income increased 7% as accelerating pricing overcame significantly higher delivered product costs, investments in the business, and unfavorable mix ▪ Year-over-year decline in acquisition adjusted fixed currency operating income margin continued to ease sequentially ▪ Acquisition adjusted fixed currency operating income increased 11% as accelerating pricing overcame higher delivered product costs and investments in the business ▪ Acquisition adjusted fixed currency operating income margin was stable versus last year ▪ Acquisition adjusted fixed currency operating income decreased 18%, as accelerating pricing was more than offset by higher delivered product costs, unfavorable Healthcare volumes and mix, and targeted investments in the business ▪ Year-over-year decline in acquisition adjusted fixed currency operating income margin significantly narrowed sequentially ▪ Acquisition adjusted fixed currency operating income increased 37% as accelerating pricing overcame higher delivered product costs and investments in the business ▪ Acquisition adjusted fixed currency operating income margin expanded significantly versus last year ($ millions – fixed currency, unaudited) 14 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g015.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4Q 2022 Balance Sheet / Cash Flow \* EBITDA and Adjusted EBITDA are non-GAAP measures. EBITDA is defined as the sum of earnings before interest, taxes, depreciation and amortization. Adjusted EBITDA is defined as the sum of EBITDA and special (gains) and charges impacting EBITDA. The inputs to EBITDA reflect the trailing twelve months of activity for the period presented. See "Non-GAAP Financial Measures" section of this presentation corresponding reconciliations. 15 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g016.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP Financial Measures 16 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g017.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP Financial Measures 17 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g018.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP Financial Measures 18 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g019.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP Financial Measures 19 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g020.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP Financial Measures 20 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g021.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP Financial Information 21 Non-GAAP Financial Information: This communication and certain of the accompanying tables include financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. ("GAAP"). These non-GAAP financial measures include: • adjusted net sales • fixed currency sales • adjusted fixed currency sales • acquisition adjusted fixed currency sales or organic sales • adjusted cost of sales • adjusted gross profit • adjusted gross margin • fixed currency operating income • adjusted operating income • adjusted fixed currency operating income • adjusted fixed currency operating income margin • acquisition adjusted fixed currency operating income or organic income • acquisition adjusted fixed currency operating income margin or organic margin • Adjusted other (income) expense • adjusted tax rate • adjusted net income attributable to Ecolab • adjusted diluted earnings per share • EBITDA • Adjusted EBITDA We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results. |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](ecl-20230214xex99d2g022.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP Financial Information (Cont.) 22 Non-GAAP Financial Information (Continued): Our non-GAAP adjusted financial measure for net sales excludes 2021 Purolite sales. Our non-GAAP adjusted financial measures for cost of sales, gross profit, gross margin, operating income, other (income) expense and interest expense exclude the impact of special (gains) and charges and (with the exception of other (income) expense) the 2021 impact of the Purolite transaction, and our non-GAAP measures for tax rate, net income attributable to Ecolab and diluted earnings per share further exclude the impact of discrete tax items. We include items within special (gains) and charges and discrete tax items that we believe can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs associated with historical trends and future results. After tax special (gains) and charges are derived by applying the applicable local jurisdictional tax rate to the corresponding pre-tax special (gains) and charges. EBITDA is defined as the sum of net income including non-controlling interest, provision for income taxes, net interest expense, depreciation and amortization. EBITDA is used in our net debt to EBITDA ratio, which we view as important indicators of the operational and financial health of our organization. We evaluate the performance of our international operations based on fixed currency rates of foreign exchange, which eliminate the translation impact of exchange rate fluctuations on our international results. Fixed currency amounts included in this release are based on translation into U.S. dollars at the fixed foreign currency exchange rates established by management at the beginning of 2022. We also provide our segment results based on public currency rates for informational purposes. Our reportable segments do not include the impact of intangible asset amortization from the Nalco and Purolite transactions or the impact of special (gains) and charges as these are not allocated to the Company's reportable segments. Acquisition adjusted fixed currency growth rates, also known as organic growth rates, are at fixed currency and exclude the results of our acquired businesses from the first twelve months post acquisition and exclude the results of divested businesses from the twelve months prior to divestiture. Further, we have excluded the results of our Purolite business for all of 2022 to remain comparable to 2021 when Purolite's results were excluded from our adjusted results. In addition, as part of the separation, we also entered into a Master Cross Supply and Product Transfer agreement with ChampionX to provide, receive or transfer certain products for a period up to 36 months. Sales of product to ChampionX under this agreement are recorded in product and equipment sales in the Corporate segment along with the related cost of sales. These transactions are removed from the consolidated results as part of the calculation of the impact of acquisitions and divestitures. These non-GAAP financial measures are not in accordance with, or an alternative to, GAAP and may be different from non-GAAP measures used by other companies. Investors should not rely on any single financial measure when evaluating our business. We recommend that investors view these measures in conjunction with the GAAP measures included in this news release. Reconciliations of our non-GAAP measures are included in the following "Non-GAAP Financial Measures" tables of this communication. We do not provide reconciliations for non-GAAP estimates on a forward-looking basis (including those contained in this news release) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of various items that have not yet occurred, are out of our control and/or cannot be reasonably predicted, and that would impact reported earnings per share and the reported tax rate, the most directly comparable forward-looking GAAP financial measures to adjusted earnings per share and the adjusted tax rate. For the same reasons, we are unable to address the probable significance of the unavailable information. |

---